Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Chlorothiazide Sodium for Injection, USP. APP expects to launch Chlorothiazide Sodium for Injection, USP in the fourth quarter of 2009.

21 Oct 2009

Comparative Effectiveness Research: One way to beat the competition

A higher percentage of companies are using Comparative Effectiveness Research to help with pricing and reimbursement decisions, according to new research from Cutting Edge Information.

21 Oct 2009

Class action lawsuit by patients who received high dosage of radiation during their CT brain perfusion scans

A class action lawsuit (Case #BC4241898) was just filed in Los Angeles Superior Court against Cedars Sinai Medical Center, GE Healthcare, Inc., and GE Healthcare Technologies on behalf of patients who received 8-times the approved dosage of radiation during their CT brain perfusion scans to diagnose strokes.

21 Oct 2009

Findings suggest a new approach to the rehabilitation of stroke patients

What's new: Researchers at MIT and San Camillo Hospital in Venice, Italy, have shown that motor impairments in stroke patients can be understood as impairments in specific combinations of muscle activity, known as synergies.

21 Oct 2009

MMPF technique for diagnosing and predicting brain syndromes

NASA technology will now be available to the medical community to help in the diagnosis and prediction of syndromes that affect the brain, such as stroke, dementia, and traumatic brain injury.

21 Oct 2009

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.

21 Oct 2009

People living with diabetes to increase up to 435 million by 2030

The latest International Diabetes Federation (IDF) data reveals that over 285 million people worldwide now live with diabetes and this number will explode to 435 million by 2030. This staggering figure does not capture the toll the disease takes on the individual. Unlike other diseases, people with diabetes are responsible for 95% of their own care and many are doing so without the proper skills and knowledge to do so.

21 Oct 2009

Cook Medical launches new products for treating peripheral arterial disease

In a tour de force of new product development and introduction, Cook Medical is introducing six new products in parallel to provide better treatment options to the physicians treating the 27 million people worldwide* afflicted with some form of peripheral arterial disease (PAD) and other diseases of the circulatory system.

21 Oct 2009

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.

21 Oct 2009

New research highlights brain's vulnerability to obesity

New research released today is affirming a long-held maxim: you are what you eat - and, more to the point, what you eat has a profound influence on the brain. The findings offer insight into the neurobiological factors behind the obesity epidemic in the United States and other developed countries.

20 Oct 2009

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

BioSante Pharmaceuticals, Inc., today announced positive safety data in its ongoing LibiGel Phase III clinical development program. For the first time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review of unblinded data, the DMC unanimously recommended continuation of the study as described in the study protocol, with no modifications.

20 Oct 2009

Cork University Hospital uses a computer simulation system in its clinical trials

SensAble Technologies, Inc., announced that its customer, the Cork University Hospital, is leading clinical trials in two European hospitals using a haptically-enabled computer simulation system for testing physician competency in administering spinal anesthesia.

20 Oct 2009

Two high blood pressure medicines effective in treating stable ischemic heart disease

Two medications commonly used to treat high blood pressure appear to be effective in treating a common type of heart disease known as stable ischemic heart disease, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

20 Oct 2009

Scientists find mechanism that protects neurons from calcium overload

Tsuruta et al. find that a lipid kinase directs a voltage-gated calcium channel's degradation to save neurons from a lethal dose of overexcitement. The study appears in the October 19, 2009 issue of the Journal of Cell Biology (www.jcb.org).

20 Oct 2009

Springer to launch "Translational Stroke Research" journal

Springer is launching a new quarterly journal Translational Stroke Research, which aims to help translate scientific discoveries from basic stroke research into the development of new strategies for prevention, assessment, treatment and repair after stroke and other forms of neurotrauma. The first issue will appear in March 2010.

20 Oct 2009

Stemedica completes pre-IND meeting with the FDA concerning allogeneic mesenchymal bone marrow cells

Stemedica Cell Technologies, Inc., a world leader in stem cell research and manufacturing, announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigative New Drug) to evaluate the safety and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.

20 Oct 2009

Rexall Diabetes Starter Kit for newly diagnosed patients

Over 40 per cent of Canadians diagnosed with a life-threatening disease, such as diabetes, feel confused or overwhelmed after leaving their doctor's office, shows a Leger Marketing survey commissioned by the Rexall family of pharmacies.

20 Oct 2009

Data on ULORIC treatment for gout flares presented at the 73rd American College of Rheumatology meeting

Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to <6.0 mg/dL and the frequency of flares with ULORIC- (febuxostat) treatment.

20 Oct 2009

Diabetes represents a global health threat

The International Diabetes Federation (IDF) released new data today showing that a staggering 285 million people worldwide have diabetes.

20 Oct 2009

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Amylin Pharmaceuticals, Inc. today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation.

20 Oct 2009

Stroke News and Research

Further Reading

APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection

Comparative Effectiveness Research: One way to beat the competition

Class action lawsuit by patients who received high dosage of radiation during their CT brain perfusion scans

Findings suggest a new approach to the rehabilitation of stroke patients

MMPF technique for diagnosing and predicting brain syndromes

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

People living with diabetes to increase up to 435 million by 2030

Cook Medical launches new products for treating peripheral arterial disease

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

New research highlights brain's vulnerability to obesity

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

Cork University Hospital uses a computer simulation system in its clinical trials

Two high blood pressure medicines effective in treating stable ischemic heart disease

Scientists find mechanism that protects neurons from calcium overload

Springer to launch "Translational Stroke Research" journal

Stemedica completes pre-IND meeting with the FDA concerning allogeneic mesenchymal bone marrow cells

Rexall Diabetes Starter Kit for newly diagnosed patients

Data on ULORIC treatment for gout flares presented at the 73rd American College of Rheumatology meeting

Diabetes represents a global health threat

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News